Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Rhiannon Coulson"'
Autor:
Elysse C. Filipe, Sipiththa Velayuthar, Ashleigh Philp, Max Nobis, Sharissa L. Latham, Amelia L. Parker, Kendelle J. Murphy, Kaitlin Wyllie, Gretel S. Major, Osvaldo Contreras, Ellie T. Y. Mok, Ronaldo F. Enriquez, Suzanne McGowan, Kristen Feher, Lake‐Ee Quek, Sarah E. Hancock, Michelle Yam, Emmi Tran, Yordanos F. I. Setargew, Joanna N. Skhinas, Jessica L. Chitty, Monica Phimmachanh, Jeremy Z. R. Han, Antonia L. Cadell, Michael Papanicolaou, Hadi Mahmodi, Beata Kiedik, Simon Junankar, Samuel E. Ross, Natasha Lam, Rhiannon Coulson, Jessica Yang, Anaiis Zaratzian, Andrew M. Da Silva, Michael Tayao, Ian L. Chin, Aurélie Cazet, Maya Kansara, Davendra Segara, Andrew Parker, Andrew J. Hoy, Richard P. Harvey, Ozren Bogdanovic, Paul Timpson, David R. Croucher, Elgene Lim, Alexander Swarbrick, Jeff Holst, Nigel Turner, Yu Suk Choi, Irina V. Kabakova, Andrew Philp, Thomas R. Cox
Publikováno v:
Advanced Science, Vol 11, Iss 23, Pp n/a-n/a (2024)
Abstract In recent decades, the role of tumor biomechanics on cancer cell behavior at the primary site has been increasingly appreciated. However, the effect of primary tumor biomechanics on the latter stages of the metastatic cascade, such as metast
Externí odkaz:
https://doaj.org/article/9b5a588e6e1648e795ea8f0708ede5c3
Autor:
Neil Portman, Heloisa H. Milioli, Sarah Alexandrou, Rhiannon Coulson, Aliza Yong, Kristine J. Fernandez, Kee Ming Chia, Ensar Halilovic, Davendra Segara, Andrew Parker, Sue Haupt, Ygal Haupt, Wayne D. Tilley, Alex Swarbrick, C. Elizabeth Caldon, Elgene Lim
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
Abstract Background Resistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed via upregulation of
Externí odkaz:
https://doaj.org/article/b6f51a6926794f258d9ad544dc70f957
Autor:
Anna Rachel Young, Jessica Da Gama Duarte, Rhiannon Coulson, Megan O’Brien, Siddhartha Deb, Alex Lopata, Andreas Behren, Suresh Mathivanan, Elgene Lim, Els Meeusen
Publikováno v:
Cancers, Vol 11, Iss 5, p 682 (2019)
Tumor antigens are responsible for initiating an immune response in cancer patients, and their identification may provide new biomarkers for cancer diagnosis and targets for immunotherapy. The general use of serum antibodies to identify tumor antigen
Externí odkaz:
https://doaj.org/article/94ed18819b1a494aa1bf8fc5fd6f94cb
Autor:
Veerle W. Daniels, Enid Y.N. Lam, Paloma Cejas, Clifford A. Meyer, Omer Gilan, Mark A. Dawson, Raga Vadhi, Ian E. Krop, Xintao Qiu, Bogdan Pasaniuc, Cynthia X. Ma, Len Taing, Klothilda Lim, Henry W. Long, Nikolas Kesten, Matthew J. Ellis, April C. Watt, Claudia Giambartolomei, Charles C. Bell, Rhiannon Coulson, Shom Goel, Eric P. Winer, Keegan Korthauer, Otto Metzger-Filho, Molly J. DeCristo, Jean J. Zhao, Alba Font-Tello, Haley BrinJones, Anthony Letai, Matthew L. Freedman, Ji-Heui Seo, Myles Brown, Joan Montero
Publikováno v:
Nature cancer, vol 2, iss 1
Nat Cancer
Nat Cancer
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) were designed to induce cancer cell cycle arrest. Recent studies have suggested that these agents also exert other effects, influencing cancer cell immunogenicity, apoptotic respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07391ad275d64c17c054e5bd0859ea39
https://escholarship.org/uc/item/0b43x9f8
https://escholarship.org/uc/item/0b43x9f8
Autor:
Kee Ming Chia, Sarah Alexandrou, C. Elizabeth Caldon, Ensar Halilovic, Alexander Swarbrick, Rhiannon Coulson, Wayne D. Tilley, Heloisa Helena Milioli, Aliza Yong, Ygal Haupt, Neil Portman, Elgene Lim, Andrew Parker, Sue Haupt, Davendra Segara, Kristine J. Fernandez
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
BackgroundResistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed via upregulation of its key re
Autor:
Davendra Segara, Elgene Lim, Kristine J. Fernandez, C. Elizabeth Caldon, Aliza Yong, Andrew Parker, Kee Ming Chia, Heloisa Helena Milioli, Ygal Haupt, Sue Haupt, Rhiannon Coulson, Neil Portman, Sarah Alexandrou, Ensar Halilovic, Wayne D. Tilley, Alexander Swarbrick
BackgroundResistance to endocrine therapy is a major clinical challenge in the management of estrogen receptor (ER)-positive breast cancer. In this setting p53 is frequently wildtype and its activity may be suppressed via upregulation of its key regu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b923afc79f5f41e0aa7626254d04d2a5
https://doi.org/10.1101/2020.06.09.140921
https://doi.org/10.1101/2020.06.09.140921
Autor:
Heloisa Helena Milioli, Sue Haupt, Aliza Yong, Sarah Alexandrou, C. Elizabeth Caldon, Rhiannon Coulson, Neil Portman, Ygal Haupt, Elgene Lim, Natasha Lam
Publikováno v:
Oncology Abstracts.
Autor:
Kee Ming Chia, Heloisa Helena Milioli, Wayne D. Tilley, Theresa E. Hickey, Davendra Segara, Aliza Yong, Catherine E Caldon, Neil Portman, Geraldine Laven-Law, Elgene Lim, Niantao Deng, Andrew Parker, Rhiannon Coulson, Alexander Swarbrick
Publikováno v:
Oncology Abstracts.
Autor:
Siddhartha Deb, Elgene Lim, Megan O’Brien, Jessica Da Gama Duarte, Alexander Lopata, Rhiannon Coulson, Els N.T. Meeusen, Andreas Behren, Anna Rachel Young, Suresh Mathivanan
Publikováno v:
Cancers
Volume 11
Issue 5
Cancers, Vol 11, Iss 5, p 682 (2019)
Volume 11
Issue 5
Cancers, Vol 11, Iss 5, p 682 (2019)
Tumor antigens are responsible for initiating an immune response in cancer patients, and their identification may provide new biomarkers for cancer diagnosis and targets for immunotherapy. The general use of serum antibodies to identify tumor antigen
Autor:
Heloisa Helena Milioli, Kee Ming Chia, Elgene Lim, Geraldine Laven-Law, Niantao Deng, Aliza Yong, Neil Portman, Alexander Swarbrick, Andrew Parker, Catherine E Caldon, Rhiannon Coulson, Wayne D. Tilley, Theresa E. Hickey, Davendra Segara
Publikováno v:
Endocrine-related cancer. 26(2)
The role of androgen receptor (AR) in endocrine-resistant breast cancer is controversial and clinical trials targeting AR with an AR antagonist (e.g., enzalutamide) have been initiated. Here, we investigated the consequence of AR antagonism using in